Tenax Therapeutics (TENX) Common Equity (2011 - 2026)

Tenax Therapeutics (TENX) has 16 years of Common Equity data on file, last reported at $114.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 4.94% year-over-year to $114.7 million; the trailing twelve-month figure through Mar 2026 stood at $114.7 million (up 4.94% YoY), and the FY2025 full-year result was $97.1 million, up 5.52% from the prior year.
• Common Equity climbed to $114.7 million in Q1 2026, from $97.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $114.7 million in Q1 2026 to a low of $1.5 million in Q4 2022.
• A 5-year average of $46.6 million and a median of $13.2 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 64.83% in 2022 and jumped 1064.15% in 2025, its largest moves.
• Tracing TENX's Common Equity over 5 years: stood at $1.5 million in 2022, then soared by 442.4% to $8.1 million in 2023, then soared by 1036.0% to $92.0 million in 2024, then gained by 5.52% to $97.1 million in 2025, then grew by 18.15% to $114.7 million in 2026.
• Business Quant data shows TENX's Common Equity at $114.7 million in Q1 2026, $97.1 million in Q4 2025, and $96.2 million in Q3 2025.